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376New-Onset Lymphopenia Assessed during Routine
Follow-up Is a Risk Factor for Relapse Postautologous
Peripheral Blood Hematopoietic Stem Cell
Transplantation in Patients with Diffuse Large
B-Cell Lymphoma
Luis F. Porrata, David J. Inwards, Stephen M. Ansell, Ivana N. Micallef, Patrick B. Johnston,
William J. Hogan, Svetomir N. MarkovicA specific predictor during routine follow-up to ascertain risk for postautologous peripheral blood hemato-
poietic stem cell transplantation (post-APHSCT) relapse in non-Hodgkin lymphoma (NHL) has not been
identified. Thus, we studied if new-onset lymphopenia measured by the absolute lymphocyte count (ALC)
was a marker of post-APHSCT NHL relapse. ALC was obtained at the time of confirmed relapse, and at
last follow-up with no relapse. From 1993 until 2005, 269 patients treated with APHSCT for diffuse large
B-cell lymphoma (DLBCL) were included in this study. Patients at last follow-up without relapse
(N5 137) had a higher ALC compared with those with low ALC at the time of confirmed relapsed
(N5 132) (median ALC 109/L of 1.66 versus 0.71, P\.0001, respectively). ALC at follow-up was a strong
predictor for relapse with an area under the curve (AUC)5 0.86 (P\.0001). An ALC\1.0 109/L at the
time of confirmed relapse had a positive predictive value of 89% and a positive likelihood ratio of 8.4 to
predict relapse post-APHSCT. Patients with an ALC $1.0 109/L (N5 147) had a cumulative incidence of
relapse of 19% versus 92%, with an ALC\1.0 109/L (N5 122) (P\ .0001). This study suggests that
new-onset lymphopenia measured by ALC can be used as marker to assess risk of DLBCL relapse during
routine follow-up for after APHSCT.
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tation, Diffuse large B cell lymphoma, RelapseINTRODUCTION that can be checked at any time during follow-upRisk factors used to assess clinical outcomes in
non-Hodgkin lymphoma (NHL) patients treated
with autologous peripheral blood hematopoietic
stem cell transplantation (APHSCT) are identified
prior to APHSCT [1]. Even though these risk factors
are critical to guide transplant physicians in the selec-
tion of which patient would benefit from APHSCT,
a limitation of these risk factors is that they are tested
at 1 point in time. A routine risk factor or a risk factorDivision of Hematology/Department of Medicine, Mayo
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6/j.bbmt.2009.10.029post-APHSCT and it retains its ability to predict
relapse at any time would be a powerful tool to help
transplant clinicians to identify patients who might
require further treatments options post-APHSCT. In
allogeneic stem cell transplantation (allo-SCT), serial
chimerism analysis could be considered a routine risk
factor that has shown to predict relapses after allo-
SCT [2-4]. In addition, high donor chimerism levels
among immune cells (T cells and natural killer [NK]
cells) might be a surrogate marker for graft-versus-tu-
mor (GVT) effect [4]. Absolute lymphocyte count
(ALC)-15 has been considered a surrogate marker
for autologous GVT effect affecting clinical outcomes
post-APHSCT [5,6]. However, in APHSCT, there
has been no specific report attesting for a routine risk
factor post-APHSCT. Thus, we set out to investigate
if the development of new-onset lymphopenia mea-
sured by the ALC at last follow-up or at the time of
confirmed relapse is a marker for relapse post-
APHSCT in patients with diffuse large B cell lym-
phoma (DLBCL).
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Patient Population
To participate in this study patients were required
to have the diagnosis of DLBCL and to have under-
gone an APHSCT. From February 2, 1993, until
December 31, 2005, 484 patients underwent autolo-
gous stem cell transplantation for NHL. Of the 484
NHL patients, 269 (56%) patients qualified for the
study. Fifty-seven patients were excluded because
they had bone marrow (BM) harvest; 60 patients
were excluded because they had the combination of
BM harvest and peripheral blood stem cells (PBSCs);
and 105 patients were excluded because they had dif-
ferent lymphoma types than DLBCL. Data from
transplant recipients were collected prospectively and
entered into a computerized database. No patients
were lost to follow-up. All patients gave written,
informed consent allowing the use of their medical
records for medical research. Approval for the retro-
spective review of these records was obtained from
the Mayo Clinic institutional review board and was
in accordance with U.S. federal regulations and the
Declaration of Helsinki.
Endpoint
The primary endpoint of the study was to assess if
new-onset lymphopenia measured by ALC at last fol-
low-up or at the time of confirmed relapse is a reliable
marker to predict relapse post-APHSCT.
Risk Factors for Relapse
Risk factors tested in the study includedALCat last
follow-up or at the time of confirmed relapse, lactate
dehydrogenase (LDH) at last follow-up, or at the
time of confirmed relapse, international prognostic
index (IPI) at last relapse pre-APHSCT1 (age $60
years, extranodal sites $2, LDH [abnormal versus
normal levels], performance status $2, and stage [I/II
versus III/IV]), disease status prior to APHSCT (com-
plete response [CR] versus partial response [PR]),
ALCat day 15post-APHSCT(ALC-15$ 500 cells/m).
This cutoff value for the ALC-15 was based on data
from our previous studies [5], and infused CD34 stem
cell count.
Conditioning Regimen
Three patients received Zevalin 0.3 mCi/kg in
combination with (BCNU) 300 mg/m2 on day 26,
etoposide 100 mg/m2 twice a day on days 25, 24,
23, and 22, ARA-C 100 mg/m2 twice a day on days
25,24,23, and22, and melphalan (Mel) 140 mg/m2
on day21 (BEAM); 9 patients received cyclophospha-
mide (Cy; 60 mg/m2) and total body irradiation (TBI;
12 Gy); 58 patients received BCNU 300 mg/m2 on
day 26, etoposide 100 mg/m2 twice a day on days25, 24, 23, and 22, ARA-C 100 mg/m2 twice a day
on days 25, 24, 23, and 22, and Cy 35 mg/kg on
day 21 (BEAC); and 199 patients received BCNU
300 mg/m2 on day 26, etoposide 100 mg/m2 twice
a day on days25,24,23, and22, ARA-C 100 mg/m2
twice a day on days 25, 24, 23, and 22, and Mel
140 mg/m2 on day 21 (BEAM).Response
Response criteria were based on the guidelines by
the new revised response criteria from the Lym-
phoma International Workshop [7]. Relapse was
defined as any new lesions or increase by $50% of
previously involved sites from nadir [7]. Time to
relapse was measured from the date of transplantation
to the date of relapse. Last follow-up was measured
from the date of transplantation to the day of last
follow-up or death in patients without any evidence
of relapse.Statistical Analysis
To assess the effect of ALC at last follow-up or at
the time of confirmed relapse on relapse post-
APHSCT, the relapse endpoint was examined both
as cumulative incidence and cumulative hazard func-
tion plot. The cumulative incidence explicitly
accounts for death from other causes besides lym-
phoma as competing risk and was estimated using
the method of Gooley and colleagues [8]. The hazard
function is the principal estimable quantity in com-
peting risks, which can be viewed as a probability of
failure specifically resulting from a cause in a small
interval of time, given that no failure of any kind
has occurred thus far. The cumulative hazard func-
tion L (t) equals the value of its corresponding hazard
function summed up to time t [9]. The cumulative
hazard function was calculated using the Nelson-
Aalen estimator [10]. The association of ALC at last
follow-up or at the time of confirmed relapse and
risk factors with the incidence of relapse was also
explored using logistic regression models.
The choice of optimal cutoff of ALC at last follow-
up or at the time of confirmed relapse was based on its
utility as a marker for relapse using box plot, receiver
operating characteristics (ROC) curves, and area under
the curve (AUC). c2-tests were used to determine rela-
tionships between categoric variables. The Wilcoxon
rank test was used to determine associations between
continuous variables and categories, and Pearson cor-
relation coefficients were used to evaluate associations
for continuous variables. The Mahalanobis distance
was used as an independent approach to assess the
robustness of the Pearson correlation. All P values
represented were 2 sided, and statistical significance
was declared at P\ .05.
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Patient Characteristics
The median age at the time of transplant for this
cohort of 269 DLBCL patients was 56 years (range:
17-76 years). Distribution of additional baseline char-
acteristics for these patients are presented in Table 1,
and are summarized based on whether patients had
an ALC \1.0 109/L versus ALC $1.0 109/L at
last follow-up or at the time of confirmed relapse.
None of the patients received purged or CD34-
selected stem cells.
The median follow-up on living patients in this
cohort was 52 months (range: 16-122 months). One-
hundred thirty-two (49%) patients had confirmed
relapse post-APHSCT with a median time to relapse
of 11 months (range: 3-84 months). Of the 135
(50%) patients that had died, 110 (81%) resulted
from relapse of lymphoma. The day 100 treatment-
related mortality (TRM) of this cohort was 5% (13/
269). Of the 109 patients with an ALC\1.0 109/L
obtained at the time of confirmed diagnosis, the me-
dian time of the decrease ALC, which correlates with
the median time of relapse in this subgroup of patients,
was 6.7 months (range: 3-47.7 months).ALC at Last Follow-up or at the Time of
Confirmed Relapse Post-APHSCT
In an attempt to identify risk factors during follow-
up that influence relapse post-APHSCT, we assessed
the utility of ALC at last follow-up or at the time of
confirmed relapse post-APHSCT as a marker for this
relevant clinical outcome. Patients without evidence
of relapse (N5 137) at last follow-up had a higher
ALC compared with those with relapse (N5 132)
post-APHSCT (median ALC 109/L of 1.66 [range:
0.13-3.69] versus 0.71 [range: 0.03-4.75], P\ .0001,
respectively). ROC and AUC analysis showed that
ALC at last follow-up or at the time of confirmed
relapse was a significant marker for relapse post-
APHSCT (AUC5 0.86, P\ .0001; Figure 1). Based
on these results an ALC at last follow-up or at the
time confirmed relapse of 1.0 109/L was considered
optimal. Therefore, this cutoff is evaluated for ALC at
last follow-up or at the time confirmed relapse in all
subsequent analysis in this study.
To assess the predictive value of ALCat last follow-
up or at the time of confirmed relapse as a test to predict
relapse at the time of follow-up post-APHSCT, a con-
tingency table was created between ALC $ versus
\1.0 109/L at last follow-up or at the time of con-
firmed relapse status post-APHSCT (Table 2). Of the
122 patients with an ALC\1.0 109/L, 109 (89%)
experienced relapse compared with 23 of 147 (16%)
of patients with an ALC $1.0 109/L (P\ .0001).
The sensitivity and specificity for ALCat last follow-upor at the time of confirmed relapse was 83% and 90%,
respectively. The relative risk to develop relapse with
an ALC\1.0 109/L at last follow-up or at the time
of confirmed relapse was 5.7 (95% confidence interval
[CI]: 3.90-8.35) and an odd ratio of 45.2 (95%CI: 21.8-
93.5). The positive predictive value with an ALC
\1.0 109/L at last follow-up or at the time of con-
firmed relapse was 89% and the negative predictive
value with an ALC $1.0 109/L at follow-up was
83%. The likelihood ratio for relapse with an ALC
\1.0 109/L at last follow-up or at the time of con-
firmed relapse was 8.4. The crude incidence rate of
relapse was 49% (132/269). The 5-year cumulative
incidence rate for an ALC \1.0 109/L at last fol-
low-up or at the time of confirmed relapse was 92%,
compared with 19% for an ALC $1.0 109/L at last
follow-up or at the time of confirmed relapse (P \
.0001) (Figure 2). The 5-year cumulative hazard rate
for an ALC\1.0 109/L at last follow-up or at the
time of confirmed relapse was 2.4, compared with 0.2
for an ALC $1.0 109/L at last follow-up or at the
time of confirmed relapse (P\ .0001).
Logistic regression models for predicting relapse
post-APHSCT further indicate that ALC at last
follow-up or at the time of confirmed relapse is signif-
icantly correlated with this clinical outcome (P \
.0001). Other significant factors for relapse post-
APHSCT in the univariate setting included ALC-15
(P\ .0001), elevated LDH at last follow-up or at the
time of confirmed relapse (P \ .0001), and infused
CD34 stem cells (P \ .02) (Table 3). When these
factors were accounted for in addition to ALC at last
follow-up or at the time of confirmed relapse in a mul-
tivariate logistic regression model (Table 3), ALC at
last follow-up or at the time of confirmed relapse
remained a significant correlate for relapse post-
APHSCT (P\ .0001). An ALC\1.0 109/L at last
follow-up or at the time of confirmed relapse was
associated with an adjusted odds ratio for relapse
post-APHSCT of 52 (95% CI: 31.8-90.1).Confounding Factors
A major limitation of retrospective study design is
the intrinsic inability of retrospective studies to control
for confounding factors that could affect the outcome
studied. To evaluate for any discrepancy between
patients’ baseline characteristics and ALC at last
follow-up or at the time of confirmed relapse post-
APHSCT, patients were divided into 2 groups: 1
group with ALC \1.0 109/L and another group
with ALC $1.0 109/L at last follow-up or at the
time of confirmed relapse post-APHSCT. The only
statistical difference between both groups was
ALC-15 (Table 1). Stage and disease status at trans-
plant showed a statistical trend; however, in a logistic
regression model, neither of them was associated
Table 1. Patient’s Baseline Characteristics Based on ALC
<1.0 versus ALC $1.0 109/L at Relapse or Last Follow-up
Characteristics
ALC <1.0
 109/L
(N5 122)
ALC $1.0
 109/L
(N5 147) P-Value
Age at transplant, years;
median (range)
56 (17-76) 56 (19-76) .6
Sex .5
Female 45 61
Male 77 86
Prognostic factors
Extranodal sites .5
0 89 100
1 24 39
2 7 7
3 2 1
LDH (U/L)
median (range)
205.5
(60-2600)
202
(110-4425)
.6
Performance status .2
0 30 50
1 87 94
2 5 3
Stage .06
I 15 19
II 16 24
III 35 22
IV 56 82
IPI index at last relapse pre-APHSCT
Age at transplant .9
$60 years 44 54
<60 years 78 93
Extranodal sites .6
>1 9 8
#1 113 139
LDH (U/L) .7
Normal 67 85
Abnormal 55 62
Performance status .5
$2 5 3
<2 117 144
Stage .5
I/II 31 43
III/IV 91 104
IPI score .8
0 21 25
1 35 53
2 47 48
3 17 19
4 2 2
Number of prior
treatment before APHSCT
.2
1 20 30
2 73 92
3 26 19
4 3 3
5 0 2
Disease status
prior to APHSCT
.06
CR 26 47
PR 96 100
Conditioning regimen .1
BEAC 31 27
BEAM 88 111
Zevalin + BEAM 0 3
Cy/TBI 3 6
Infused CD34 stem cells
106/kg: median (range)
3.58
(2-10.35)
4.1
(2-14.85)
.3
Post-APHSCT growth factor .4
G-CSF 37 38
GM-CSF 85 109
ALC-15 cells/mL <.0001
$500 45 106
<500 77 41
(Continued )
Table 1. (Continued )
Characteristics
ALC <1.0
 109/L
(N5 122)
ALC $1.0
 109/L
(N5 147) P-Value
Hemoglobin at the time
of confirmed relapse
or last follow-up: median
(range), g/dL
12.5
(7.8-15.4)
13.3
(7.6-16.6
.3
WBC count at the time
of confirmed relapse
or last follow-up: median
(range) 109/L
5.25
(1.0-12.3)
6.0
(1.7-12.5)
0.6
ANC at the time of confirmed
relapse or last follow-up:
median (range) 109/L
3.3
(0.67-11.52)
3.3
(0.19-10.08)
.7
Plts at the time of confirmed
relapse or last follow-up:
median (range) 109/L
165.5
(5-486)
181
(11-462)
.1
BM pre-APHSCT .2
Positive 3 9
Negative 119 138
Rituxan pre-APHSCT 1 1 .8
Yes 52 65
No 70 82
Post-APHSCT consolidation RT .8
Yes 15 20
No 107 127
ALC indciates absolute lymphocyte count; ALC-15. absolute lympho-
cyte count at day 15 after transplant; APHSCT, autologous peripheral
blood hematopoietic stem cell transplantation; ANC, absolute neutro-
phil count; BEAC, BCNU, etoposide, ARA-C, cyclophosphamide;
BEAM, BCNU, etoposide, ARA-C, melphalan; BM, bone marrow; CR,
complete remission; Cy, cyclophosphamide; G-CSF, granulocyte-colony
stimulating-factor; GM-CSF, granulocyte-macrophage colony-stimulat-
ing factor; IPI, international prognostic index; LDH, lactate dehydroge-
nase; Plts, platelets; PR, partial remission; TBI, total body irradiation;
RT, radiation therapy; WBC, white blood cell.
Biol Blood Marrow Transplant 16:376-383, 2010 379Lymphopenia at Follow-up Post-APHSCT in DLBCL Associated with Relapsewith ALC at last follow-up or at the time of confirmed
relapse: disease status at transplant (P5 0.4) and stage
(P5 0.4). However, we identified a positive correla-
tion between ALC-15 and ALC at last follow-up or
at the time of confirmed relapse before (r5 .34, P\
.0001) and after (r5 .31, P\ .0001) outliers identified
by the Mahalanobis distance were eliminated.Figure 1. ROC curve to evaluate ALC at follow-up post-APHSCT as
a marker for relapse. Specifically, this curve plots the sensitivity versus
1 minus the specificity of this marker for relapse. The corresponding
AUC analysis indicated that ALC at follow-up post-APHSCTwas indeed
a significant marker for relapse (AUC5 0.86, P\.0001).
Table 2. Contingency Table
Relapse at Follow-up Post-APHSCT
Count Yes No
ALC <1.0 109/L at last follow-up
or at the time of confirmed
relapse post-APHSCT
109 (a) 13 (b) 122
ALC $1.0 109/L at last follow-up
or at the time of confirmed
relapse post-APHSCT
23 (c) 124 (d) 147
132 137 269
ALC indicates absolute lymphocyte count; APHSCT, autologous periph-
eral blood hematopoietic stem cell transplantation.
Letters: (a)5 true positive; (b)5 false positive; (c)5 false negative; and
(d)5 true negative
Formulas: Sensitivity5 a/(a + c); Specificity5 d/(b + d); positive predic-
tive value5 a/(a + b); negative predictive value5 d/(c + d); positive like-
lihood ratio5 Sensitivity/(1 – Specificity); odd ratio5 ad/bc; and
relative risk5 [a/(a + b)]/[c/(c + d)].
380 Biol Blood Marrow Transplant 16:376-383, 2010L. F. Porrata et al.Furthermore, confounding factors that could lead
to lymphopenia were assessed. None of the patients
in this study were human immunodeficiency virus
(HIV) positive or received post-APHSCT mainte-
nance rituximab. There was no association between
post-APHSCT consolidation radiation therapy and
ALC at last follow-up or at the time of confirmed
relapse 109/L post-APHSCT (P5 .8). No associa-
tion was also observed between the number of prior
treatments before APHSCT and ALC at last follow-
up or at the time of confirmed relapse 109/L post-
APHSCT (P5 .2): 1 treatment (median ALC5 1.2
[range: 0.13-2.9]); 2 treatments (median ALC5 1.1
[range: 0.1-4.75]); 3 treatments (median ALC5 0.8
[range: 0.06-2.8]); 4 treatments (median ALC5 1.0
[range: 0.25-3.2]); and 5 treatments (median
ALC5 1.9 [range: 1.89-2.7]). Similarly, no association
was identified between the conditioning regimens and
ALC at last follow-up or at the time of confirmed
relapse at follow-up 109/L post-APHSCT (P5 .5):
BEAC (median ALC5 1.0 [range: 0.25-3.07]); BEAMFigure 2. Cumulative incidence for relapse based on ALC at follow-up
post APHSCT. Patients with an ALC\1.0 109/L at follow-up experi-
enced a higher cumulative incidence of 92% compared with a cumulative
incidence of 19% for patients with an ALC $1.0 109/L at follow-up
post-APHSCT.(median ALC5 1.1 [range: 0.06-4.75]); CTX/TBI
(median ALC5 1.4 [range: 0.24-2.8]); and Zevalin/
BEAM (median ALC5 1.6 [range: 1.0-2.5]). In addi-
tion, there was no difference between both groups
(ALC$ 1 versus ALC\1) regarding hemoglobin,
white blood cell (WBC) count, absolute neutrophil
count (ANC), and platelet count obtained at last
follow-up or at the time of confirmed relapse (Table 1).
No differences between both groups were also
observed regarding the use of rituxan pre-APHSCT
and positive BM involvement pre-APHSCT. Of the
132 patients with relapse, 12 (9%) had positive BM
involvement: 2 patients with the ALC $1 109/L
group and 10 patients in the ALC\1 109/L group
at the time of confirmed relapse.
ALC and LDH at Last Follow-up or at the Time
of Confirmed Relapse Post-APHSCT
LDH at last follow-up or at the time of confirmed
relapse post-APHSCT in this study was also identified
as a risk factor for relapse post-APHSCT. LDH is
considered a surrogate marker for tumor burden in
NHL. Similarly, ALC can be considered a surrogate
marker of host immunity [11]. Thus, using these 2
standarized, low-cost biomarkers, we assessed if there
was any correlation between tumor burden and host
immunity. We identified a negative correlation be-
tween ALC and LDH at last follow-up or at the time
of confirmed relapse before (r52.34, P \ .0001)
and after (r52.32, P\ .0001) outliers identified by
the Mahalanobis distance were eliminated (Figure 3).
Because of this negative correlation and the fact that
both markers are predictor of relapse when check dur-
ing follow-up post-APHSCT, we assessed the cumula-
tive incidence of relapse combining both markers. We
found lower cumulative incidence of relapse in patients
with a higher ALC compared with patients with low
ALC regardless if the LDH was normal or abnormal
at last follow-up or at the time of confirmed relapse
post-APHSCT (Figure 4).DISCUSSION
The current risk factors used to assess clinical
response in NHL patients treated with APHSCT are
identified prior to APHSCT such as the IPI [1]. How-
ever, a limitation of these risk factors is that they are
tested at 1 point in time and they are assumed to retain
their predictive ability to determine clinical response
at any time post-APHSCT. An ideal risk factor is
a risk factor that not only has the ability to predict
future clinical outcomes, but also clinical outcome at
any given time point after therapy has been imple-
mented. Therefore, we set out to investigate if ALC
checked at any given time during follow-up is a marker
of relapse in DLBCL patients treated with APHSCT.
Table 3. Univariate and Multivariate Analysis for Relapse
Univariate Analysis Multivariate Analysis
Characteristics Estimate Standard Error c2 P-Value Estimate Standard Error c2 P-Value
Age >60 years 20.09 0.13 0.54 .5
ALC-15 < 500 cells/mL 20.69 0.13 28.28 <.0001 20.31 0.20 2.39 .1
ALC <1.0 109/L at last follow-up or at the
time of confirmed relapse
21.9 0.19 105.53 <.0001 21.68 0.20 69.35 <.0001
LDH abnormal at last follow-up or at the
time of confirmed relapse
20.9 0.15 42.41 <.0001 20.72 0.21 11.83 <.0006
CD34 20.1 0.06 4.8 <.02 20.11 0.10 1.07 .3
Extranodal disease >1 at last relapse pre-APHSCT 20.21 0.25 0.68 .4
LDH abnormal at last relapse pre-APHSCT 20.46 0.19 1.88 .4
PS >1 at last relapse pre-APHSCT 20.02 0.36 0.01 .9
Stage III/IV at last relapse pre-APHSCT 20.01 0.14 0.01 .9
IPI >1 at last relapse pre-APHSCT 20.14 0.12 1.34 .2
ALC indicates absolute lymphocyte count; ALC-15, absolute lymphocyte count at day 15 after transplant; IPI, international prognostic index; LDH, lac-
tate dehydrogenase; PS, performance status.
Biol Blood Marrow Transplant 16:376-383, 2010 381Lymphopenia at Follow-up Post-APHSCT in DLBCL Associated with RelapseOur study shows that DLBCL patients with con-
firmed relapse at follow-up had a lower ALC com-
pared with those without evidence of relapse at last
follow-up post-APHSCT. A low ALC at last follow-
up or at the time of confirmed relapse was associated
with a high odd ratio, high relative risk, high sensitiv-
ity, high positive predictive value, high cumulative
hazard rate, and high cumulative incidence for relapse
compared with patients with a high ALC at last follow-
up or at the time of confirmed relapse that was associ-
ated with a high specificity, low negative predictive
value, and low cumulative hazard rate and cumulative
incidence for relapse post-APHSCT.
Within the limitations of our retrospective study,
these data can only be viewed as hypothesis generating.
Based our findings the association of decreased ALC
and increased risk of NHL relapse (coincident with
elevation of serum LDH concentrations) could be
the result of either: (1) primary failure of immuneFigure 3. Scatterplot comparing ALC at follow-up and LDH at follow-
up post-APHSCT. A negative correlation was identified between ALC
and LDH at follow-up post-APHSCT. Arrows indicate those points
that according to the Mahalanobis distances are outliers. R1 and R2 cor-
respond to the Pearson’r values before and after eliminating possible out-
liers. The regression line was estimated after the elimination of outliers.surveillance yielding a permissive systemic immuno-
logic environment allowing for clinical NHL relapse;
or (2) primary NHL relapse driven by tumor-
associated events, which in turn, produce mediators
of immune suppression manifesting as a decrease in
ALC. Our current data is unable to distinguish
between these 2 possibilities. However, to the extent
that ALC can be viewed as a surrogate marker of im-
mune competence, there are numerous examples in
which the presence of competent systemic immunity
directly impacts NHL biology. Possibly the best
clinical example in support of this notion is the natural
history of posttransplant lymphoproliferative disor-
ders (PTLD). In this context, a frequently effective
therapeutic intervention against the NHL is a simple
reduction of immunosuppression, currently employed
as ‘‘standard of care.’’ An associated, albeit less pro-
found clinical observation is the association of ALC
and efficacy of rituximab therapy in patients with low
gradeNHL [12]. Patients with normal ALChave a sig-
nificantly higher likelihood of good clinical outcomes
following rituximab therapy relative to those with
lowALC. Assuming that 1 aspect of effective rituximab
therapy is its ability to mediate antibody-dependent
cellular cytotoxicity (ADCC), presence of competent
immunity (reflected by normal ALC) appears critical
to clinical outcomes. However, despite these associa-
tions, a mechanistic explanation for the increased risk
for NHL in patients that demonstrate low ALC can
only be addressed in an appropriately designed pro-
spective clinical trial where relevant analyses of both
systemic immunity and tumor phenotype can be stud-
ied. Such an endeavor is currently under way. Never-
theless, based on the presented data, the association
between ALC andNHL relapse seems clinically useful
in judging risk for NHL relapse in patients in clinical
follow-up post-APHSCT.
Tominimize the inherited biases of a retrospective
study the following steps were taken. First, we selected
only patients that had their stem cell collected through
Figure 4. Cumulative incidence for relapse based on the ALC and LDH at follow-up post-APHSCT. Patients with an ALC\1.0 109/L experienced
a higher cumulative incidence of relapse regardless if the LDH was normal or abnormal at follow-up compared with a lower cumulative incidence of
relapse with an ALC $1.0 109/L regardless if the LDH was normal or abnormal at follow-up post-APHSCT.
382 Biol Blood Marrow Transplant 16:376-383, 2010L. F. Porrata et al.the PB as PBSC collection is considered the preferred
mode of stem cell collection for autologous SCT with
lower side effects and faster engraftment compared
with stem cells collected by BM harvest [13]. Second,
we selected patients with DLBCL because DLBCL is
themost common lymphoma type for which APHSCT
is indicated as the standard of care for patients that
failed initial therapy [14]. Another reason to only select
DLBCL patients was to have a homogenous group of
patients. The authors of this study are well aware that
within DLBCL, 3 biologically distinct categories of
DLBCL have been described based on gene expression
profiling including germinal center B cell-like (GCB),
activated B cell-like, and type 3, with a predominant
T cell signature [15]. Patients with GCB derived
DLBCL have a higher chance of cure than non-GCB
patients when treated with conventional anthracycline
based chemotherapy [16]. However, our group re-
cently published similar clinical outcome with GCB
DLBCL patients and non-GCB DLBCL patients
treated with autologous SCT, suggesting that the use
of intensified therapy may overcome the negative im-
pact of the non-GCB phenotype [17]. Third, we could
not identify any medications or infections that could
have affected the ALC at follow-up. Fourth, outside
from ALC-15, all the baseline patients’ characteristics
were balanced between the ALC $ versus
\1.0 109/L groups, including specifically the num-
ber of prior treatments before APHSCT, as well as
none of the patients received Flu-based therapy.
On the other hand, the strength of this study in-
cluded the analysis of a large cohort of patients, with
enough follow-up to attest for the use of ALC at fol-
low-up post-APHSCT as a marker for relapse. Second,
the study identified a worldwide, standarized, low-cost
risk factor in the ALC at follow-up to assess relapse
post-APHSCT. Third, to our knowledge, this studyidentified for thefirst timeALCat follow-up as amarker
to assess relapse at any given point in time during fol-
low-up post-APHSCT in DLBCL. Thus, our study
suggests that theALCat follow-up can be used as a sim-
ple, inexpensive tool to alert transplant clinicians of re-
lapse during follow-up post-APHSCT in DLBCL
Financial disclosure: The authors have nothing to
disclose.REFERENCES
1. Lerner RE, ThomasW,Defor TE,Weisdorf DJ, Burns LJ. The
international prognostic index assessed at relapse predicts out-
comes of autologous transplantation for diffuse large-cell non-
Hodgkin’s lymphoma in second complete or partial remission.
Biol Blood Marrow Transplant. 2007;13:486-492.
2. Huisman C, de Weger RA, de Vries L, Tilanus MGL,
Verdonck LF. Chimerism analysis within 6months of allogeneic
stem cell transplantation predicts relapse in acute myeloid leuke-
mia. Bone Marrow Transplant. 2007;39:285-291.
3. Lawler M, McCann SR, Marsh JCW, et al. Serial chimerism
analysis indicate that mixed haematopoietic chimerism influ-
ences the probability of graft rejection and disease recurrence
following allogeneic stem cell transplantation (SCT) for severe
aplastic anaemia (SAA): indication for routine assessment of chi-
merism post-SCT for SAA. Br J Haematol. 2008;144:933-945.
4. Baron F, Sandmaier BM. Chimerism and outcomes after alloge-
neic hematopoietic cell transplantation following nonmyeloa-
blative conditioning. Leukemia. 2006;20:1690-1700.
5. Porrata LF, Markovic SN. Timely reconstitution of immune
competence affects clinical outcome following autologous
stem cell transplantation. Clin Exp Med. 2004;4:78-85.
6. Porrata LF. Clinical evidence of autologous graft versus tumor
effect. Am J Immunol. 2009;5:1-7.
7. Cheson BD, Pfistner B, Juweid ME, et al. Revised response cri-
teria for malignant lymphoma. J Clin Oncol. 2007;25:579-586.
8. Gooley TA, LeisenringW, Crowley J, Storer BE. Estimation of
failure probabilities in the presence of competing risks: new rep-
resentation of old estimators. Stat Med. 1999;18:695-706.
9. Dignam JJ, KocherginskyMN.Choice and interpretation of sta-
tistical tests used when competing risks are present. J Clin Oncol.
2008;26:4027-4034.
10. Ghosh D. Proportional hazards regression for cancer studies.
Biometrics. 2008;64:141-148.
Biol Blood Marrow Transplant 16:376-383, 2010 383Lymphopenia at Follow-up Post-APHSCT in DLBCL Associated with Relapse11. Porrata LF. Host immunity and survival. Leukemia Lymphoma.
2008;49:843-844.
12. Behl D, Ristow K, Markovic SN, et al. Absolute lymphocyte
count predicts therapeutic efficacy of rituximab in follicular lym-
phomas. Br J Haematol. 2007;137:409-415.
13. Bensinger DT. Optimization of peripheral blood stem cell col-
lection. Curr Opin Hematol. 1995;2:219-226.
14. Phillip T, Guglielmi C, Hagenbeek A, et al. Autologous bone
marrow transplantation as compared with salvage chemotherapy
in relapse of chemotherapy-sensitive non-Hodgkin’s lymphoma.
N Engl J Med. 1995;333:1540-1545.15. Alizadeh AA, EisenMB,Davis RE, et al. Distinct types of diffuse
large B-cell lymphoma identified by gene expression profiling.
Nature. 2000;403:503-511.
16. Rosenwald A, Wright G, ChanWC, et al. The use of molecular
profiling to predict survival after chemotherapy for diffuse large
B-cell lymphoma. N Engl J Med. 2002;346:1937-1947.
17. Costa LJ, Feldman Al, Micallef IN, et al. Germinal center
B (GCB) and non-GCB cell-like diffuse large B cell lympho-
mas have similar outcomes following autologous haemato-
poietic stem cell transplantation. Br J Haematol. 2008;142:
404-412.
